ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO281

Gemcitabine Hemolytic Uremic Syndrome (HUS) Associated with a New Complement Factor B (CFB) Mutation Successfully Treated with Eculizumab

Session Information

Category: Onconephrology

  • 1700 Onconephrology


  • Lawanto, Stephanie, UMass Chan Med School-Baystate, Springfield, Massachusetts, United States
  • Hodgins, Spencer, UMass Chan Med School-Baystate, Springfield, Massachusetts, United States
  • Landry, Daniel L., UMass Chan Med School-Baystate, Springfield, Massachusetts, United States
  • Mulhern, Jeffrey, UMass Chan Med School-Baystate, Springfield, Massachusetts, United States
  • Braden, Gregory Lee, UMass Chan Med School-Baystate, Springfield, Massachusetts, United States

Gemcitabine(G) HUS often causes chronic kidney disease or ESRD.We describe a patient(pt) who received a large cumulative dose of G who had a CFB mutation which caused dialysis dependency treated with eculizumab(E) successfully allowing cessation of dialysis.

Case Description

A 46 yr old woman with ER/PR positive & HER/2 negative breast cancer metastatic to her spine, liver and thoracic nodes was given G, 1500 mg on days 1 & 8 of ever 3 week cycle. After receiving 28040 mg/m2 of G she developed a BP of 160/100mmHg, dyspnea,an increase in serum creatinine from 1.3 to 3.7 mg/dl and MAHA with a Hg of 5.4 gm/dl, platelets 100,000, haptoglobin < 10 mg/dl, and LDH of 1046 IU/L & schistocytes on blood smear. C3 & C4 and ADAMTS13 were normal. Hepatitis A B&C, ANA, anti-DNA, cryos, ANCA, Shiga toxin, cardiolipin ab, rheumatoid factor, immunofioxation, INR, PTT, platelet antibodies, DAT, & direct coombs were all normal. After 2 plamaphareses a renal biopsy showed: Light: endothelial swelling, thickening of glomerular basement membranes,with double contours & intraluminal thrombi. IF :no tissue. EM: corrugated basememnt membranes with total foot process fusion and no immune deposits. She rapidly progressed to hemodialysis. Complement gene sequencing (Invitae, San Francisco,CA) showed a CFB mutation c.1937A>C
(p.Tyr646Ser). She then received E 900 mg iv weekly x 4 & 1200 mg every other week for 4 months. MAHA quickly abated & after 3 months dialysis was stopped with a creatinine of 1.8 mg/dl. She died 4 months later from her cancer.


We believe G-HUS occurs from a 2 hit hypothesis. G induces apoptosis & cell death in cultured bovine endothelial cells ( AJ van Hall Cell Signal 34:86, 2017).This in the renal vessels coupled with a gain of function mutation in CFB could be enough to induce HUS. Several studies suggest E can treat G-HUS but they did not study complement mutations. Any pt with G-HUS should have complement gene testing performed & if positive E can induce MAHA remission & reverse dialysis dependency.